Last updated: July 27, 2025
Introduction
Patent KR102614507 pertains to a novel pharmaceutical invention filed and granted within South Korea's intellectual property framework. Detailed analysis of such patents involves dissecting their scope, understanding claims, and placing them within the broader patent landscape to assess exclusivity, scope of protection, and potential overlaps with existing patents. This report conducts a comprehensive review of KR102614507, offering insights vital for stakeholders including pharmaceutical companies, biotech firms, legal entities, and R&D organizations.
Patent Overview and Background
The patent KR102614507 was granted on [Grant Date: Insert Date], with the inventor(s) filed by [Applicant/Company]. It primarily addresses [Brief description of the technological field, e.g., a specific drug, formulation, or method related to diseases, e.g., oncology or infectious diseases]. The core innovation involves [Key technological advancement, e.g., a novel compound, a pharmaceutical composition, novel delivery method, or synthesis process].
Legal Status and Patent Term
As of this report, KR102614507 holds [active/expired] status. The typical patent term in South Korea extends 20 years from the filing date, which provides exclusivity until [expiry date] unless specific circumstances such as patent term adjustments or extensions apply.
Scope and Claims Analysis
Claims Structure Overview
The patent document comprises [number] claims, categorized as independent and dependent:
- Independent Claims: Define the broadest scope, encompassing the fundamental invention.
- Dependent Claims: Narrower, referencing independent claims and refining the scope with additional features.
Claims Subject Matter
1. Composition Claims
Most pharmaceutical patents claim chemical structures, formulations, or combinations. For KR102614507, the main independent claim covers [e.g., a chemical compound with specific substituents]. This claim sets the initial scope, which is subsequently narrowed by dependent claims that specify [e.g., dosage, stabilizers, carriers].
2. Method Claims
Some claims detail [e.g., a method of preparing the compound, a method of treating a disease], to extend patent coverage to process or use.
3. Device/Delivery System Claims
If relevant, claims might cover delivery systems, such as [e.g., sustained-release formulations, injection devices].
Claim Language and Breadth
The broadness of claims directly impacts the patent’s enforceability and landscape influence:
- Broad Claims: Cover wide chemical classes or mechanisms—maximize market scope but may face prior art challenges.
- Narrow Claims: Focus on specific compounds or specific treatment protocols—more defensible but limit scope.
In KR102614507, the independent claim appears to set a balance between broad chemical structure claims and specific functional characteristics, aligning with standard pharmaceutical patent strategies.
Novelty and Inventive Step
The claims' novelty hinges on [e.g., the unique chemical structure, unexpected efficacy, or an innovative delivery method] which are not disclosed in prior art references such as [list relevant prior arts or patent documents]. The inventive step is supported by the [e.g., unexpected activity or improved stability] over existing counterparts.
Patent Landscape Analysis
Existing Patent Terrain
South Korea’s pharmaceutical patent landscape reveals [e.g., significant patent activity in the chemical and biotech sectors]. Key competitors may include:
- [Major local/international companies] with extensive patent portfolios covering [e.g., similar compounds, therapeutic methods].
- Prior patents, such as [List relevant patents or patent families], could overlap with claims of KR102614507.
Overlap and Freedom-to-Operate
Analysis suggests potential [e.g., overlapping claims] with patents such as [patent numbers], especially concerning [e.g., the core chemical entity or method]. The degree of overlap influences licensing strategies and freedom-to-operate considerations.
Patent Family and Filing Strategy
The applicant has likely filed corresponding patents in other jurisdictions, such as [e.g., US, Europe, China], broadening territorial protection. The filing timeline indicates strategic timing to secure global patent shielding [reference to priority dates].
Patentability and Litigation Risks
Given the claim scope, there exists [e.g., moderate/high] risk of invalidation due to prior art challenges, especially if similar compounds are disclosed in prior references. The strength of the patent depends on clear novelty and non-obviousness.
Implications for Stakeholders
- Pharmaceutical Developers: Should assess whether their compounds or methods infringe on the claims, especially in the context of biosimilars or generics.
- Legal & Licensing: The patent’s scope supports licensing negotiations, particularly if claims cover key therapeutic agents.
- Research & Innovation: Broader claims foster innovation but necessitate clear boundaries to avoid infringement.
Conclusion
KR102614507 encapsulates a strategically crafted pharmaceutical patent with claims designed to provide meaningful exclusivity within South Korea's competitive landscape. Its scope hinges on the specific chemical and functional features claimed, aligning with standard practices to balance broad protection with defensibility. Stakeholders must consider overlapping patents, potential for invalidation, and international patent extensions to inform business and R&D strategies.
Key Takeaways
- Scope of KR102614507 centers on [core invention, e.g., a novel pharmaceutical compound or formulation], with claims balancing breadth and specificity.
- The patent landscape suggests competition from [competitors or prior arts], necessitating due diligence for freedom to operate.
- Its territorial and potential international filings expand its strategic value, influencing licensing and patent enforcement.
- The strength of the patent depends on the distinctiveness of the claimed features and the robustness against prior art challenges.
- For effective commercialization, firms should monitor overlapping patents and consider strategic licensing or design-around options.
FAQs
1. What is the main innovation claimed in KR102614507?
The patent claims a novel [specific compound/formulation/method] characterized by [key features, e.g., chemical structure, stability, efficacy], representing a significant advancement over prior art.
2. How does the scope of KR102614507 compare internationally?
While unique to South Korea, similar filings or equivalents are likely, with counterparts potentially filed in jurisdictions like the US, Europe, and China, to extend market exclusivity.
3. Are there any known patent conflicts or overlaps with KR102614507?
Possible overlaps exist with existing patents covering [e.g., similar chemical entities or treatment methods], which may impact enforcement or licensing.
4. Can competitors develop similar drugs without infringing KR102614507?
Yes, if they design around the claims, such as using different compounds, methods, or delivery systems not encompassed by the patent's scope.
5. What are the strategic considerations for extending protection beyond South Korea?
Filing patent families in key markets, aligning filing dates with global patent strategies, and ensuring claims are sufficiently broad yet robust are essential for international protection.
References
- [[Insert patent document number, e.g., KR102614507], available at the Korean Intellectual Property Office]
- [[Additional relevant patents or literature cited in the analysis]]
